Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufactu...
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-D...
Primera Analytical Solutions (Primera), an FDA-compliant analytical Contract Research Organization (CRO), has selected Cenevo’s Labguru electro...
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that it has submitted a marketing authorization application (M...
Bavarian Nordic A/S announced a new order valued at USD 22.5 million from the Public Health Agency of Canada (PHAC) for the Company’s mpox an...
MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative disea...
Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic...
Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2 Agilent Technologies Inc. announced ...
A team from Knobbe Martens obtained a decisive win for medical device manufacturer Applied Medical against Medtronic, Inc. in an antitrust case involving...
BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced that the Biologics License Application (BLA) for the treatme...
Decision removes last patent hurdle as Geneoscopy advances ColoSense®, its RNA-based noninvasive colorectal cancer screening test Geneosco...
Ascentage Pharma Group International , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commerc...
Rare Patient Voice’s 200,000+ registered patients and caregivers expand Konovo’s ability to deliver connected insights across a broad range o...
As regulators worldwide intensify scrutiny of per- and polyfluoroalkyl substances (PFAS), laboratories are being pushed into a new era of sensitivity, sp...
© 2026 Biopharma Boardroom. All Rights Reserved.
